{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:38:57Z","timestamp":1773272337042,"version":"3.50.1"},"reference-count":51,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The standard therapy used in the treatment of Duchenne muscle dystrophy (<jats:styled-content style=\"fixed-case\">DMD<\/jats:styled-content>) is corticoids, such as deflazacort and prednisone. However, they have limited therapeutic value, and their combination with drugs already in use to treat other human diseases could potentially increase corticoid outcomes in <jats:styled-content style=\"fixed-case\">DMD<\/jats:styled-content>. In the present study, we evaluated whether a combined therapy of the corticoid deflazacort with doxycycline could result in greater improvement in <jats:italic>mdx<\/jats:italic> dystrophy than deflazacort alone. Deflazacort alone or deflazacort\/doxycycline were administered for 36\u00a0days (starting on postnatal day 0) in drinking water. Histopathological, biochemical (creatine kinase), functional (forelimb muscle grip strength and fatigue) parameters and inflammatory markers (<jats:styled-content style=\"fixed-case\">MMP<\/jats:styled-content>\u20109, <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010<jats:italic>\u03b1<\/jats:italic>,<jats:styled-content style=\"fixed-case\"> NF<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">kB<\/jats:styled-content>) were evaluated in <jats:italic>biceps brachii<\/jats:italic> and diaphragm muscles of the <jats:italic>mdx<\/jats:italic> mice. The combined therapy was superior in improving the dystrophic phenotype compared to monotherapy. The primary results were observed in attenuating muscle fatigue, decreasing muscle total calcium and inflammatory markers and increasing <jats:italic>\u03b2<\/jats:italic>\u2010dystroglycan, a main component of the dystrophin\u2010protein complex. Furthermore, the combined therapy was effective in preventing the loss of body mass observed with deflazacort alone at this very early stage of therapy. The present study offers preclinical data to support further studies with deflazacort\/doxycycline combined therapy in <jats:styled-content style=\"fixed-case\">DMD<\/jats:styled-content> clinical trials.<\/jats:p>","DOI":"10.1111\/1440-1681.12417","type":"journal-article","created":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T04:14:04Z","timestamp":1431317644000},"page":"788-794","source":"Crossref","is-referenced-by-count":5,"title":["Co\u2010administration of deflazacort and doxycycline: a potential pharmacotherapy for Duchenne muscular dystrophy"],"prefix":"10.1111","volume":"42","author":[{"given":"Juliano Alves","family":"Pereira","sequence":"first","affiliation":[{"name":"Department of Structural and Functional Biology Institute of Biology State University of Campinas (Unicamp) Campinas S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Julia","family":"Marques","sequence":"additional","affiliation":[{"name":"Department of Structural and Functional Biology Institute of Biology State University of Campinas (Unicamp) Campinas S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Humberto","family":"Santo Neto","sequence":"additional","affiliation":[{"name":"Department of Structural and Functional Biology Institute of Biology State University of Campinas (Unicamp) Campinas S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23528"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(00)01770-3"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24177"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2010.10.004"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.4103\/1817-1737.84777"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/138955712798868977"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2013.05.001"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.76"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2004.05.006"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000148485.00049.B7"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20812"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmr.2012.08.003"},{"key":"e_1_2_7_14_1","first-page":"16","article-title":"Prednisolone treatment and restricted physical activity further compromise bone of mdx mice","volume":"12","author":"Novotny SA","year":"2012","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(97)00104-X"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12139"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2006.05.010"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0021-8782.2001.00008.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/355696a0"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073224"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/dvdy.24031"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23468"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1078\/0171-9335-00315"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2006.02.004"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2005.01.007"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.2006.04394.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.2004.04332.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21154"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065831"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192571199"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-8966(01)00198-5"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-1024com"},{"key":"e_1_2_7_33_1","first-page":"139","article-title":"Doxycycline increases prednisolone sensitivity in childhood acute lymphoblastic leukaemia","volume":"13","author":"Sytczynski J","year":"2009","journal-title":"Contemp. Oncol. (Pozn)."},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15794-2"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsmc.2013.02.006"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/PHM.0000000000000091"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20646"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2009.09.015"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7793.2001.t01-1-00657.x"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00015.2007"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002060-200211001-00010"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02877711"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2007.01648.x"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200906-0837OC"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-0649"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5273(90)90082-G"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1242"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.05-4821fje"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21523"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23331"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(94)00276-T"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-8966(01)00232-2"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1440-1681.12417","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1440-1681.12417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:46:11Z","timestamp":1695570371000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1440-1681.12417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1111\/1440-1681.12417"],"URL":"https:\/\/doi.org\/10.1111\/1440-1681.12417","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}